The PAAT describes post-authorization activity for Adcetris, a product which contains the medicinal ingredient brentuximab vedotin. Based on Health Canada's review, the benefit/risk profile of Adcetris is favourable for: 1. The treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates; 2. The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen. Read more here.
No comments:
Post a Comment